Tech Company Financing Transactions

Remix Therapeutics Funding Round

Remix Therapeutics, based in Cambridge, secured $60 million from The Column Group, Alexandria Venture Investments and Arch Venture Partners.

Transaction Overview

Company Name
Announced On
1/3/2024
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Undisclosed
Proceeds Purpose
The company intends to use the funds to support clinical development of its lead program, REM-422, and further advancement of a pipeline of RNA processing targeted therapeutics.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Kendall Sq. Building 200
Cambridge, MA 02139
USA
Phone
Undisclosed
Email Address
Not Recorded
Overview
Remix Therapeutics is developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways. Powered by our proprietary REMaster technology platform, we can now create medicines with the unique ability to alter the way genes are read from the genome, correcting dysregulation or eliminating the gene message altogether.
Profile
Remix Therapeutics LinkedIn Company Profile
Social Media
Remix Therapeutics Company Twitter Account
Company News
Remix Therapeutics News
Facebook
Remix Therapeutics on Facebook
YouTube
Remix Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chairman
Kevin Bitterman
  Kevin Bitterman LinkedIn Profile  Kevin Bitterman Twitter Account  Kevin Bitterman News  Kevin Bitterman on Facebook
Chief Operating Officer
Heather Wasserman
  Heather Wasserman LinkedIn Profile  Heather Wasserman Twitter Account  Heather Wasserman News  Heather Wasserman on Facebook
Chief Scientific Officer
Peter Smith
  Peter Smith LinkedIn Profile  Peter Smith Twitter Account  Peter Smith News  Peter Smith on Facebook
Vice President
Dominic Reynolds
  Dominic Reynolds LinkedIn Profile  Dominic Reynolds Twitter Account  Dominic Reynolds News  Dominic Reynolds on Facebook
Vice President
Jesse Smith
  Jesse Smith LinkedIn Profile  Jesse Smith Twitter Account  Jesse Smith News  Jesse Smith on Facebook
Vice President
Fred Vaillancourt
  Fred Vaillancourt LinkedIn Profile  Fred Vaillancourt Twitter Account  Fred Vaillancourt News  Fred Vaillancourt on Facebook
VP - Bus. Development
Alex Harding
  Alex Harding LinkedIn Profile  Alex Harding Twitter Account  Alex Harding News  Alex Harding on Facebook


 

 

Browse more venture capital transactions:

Prev: 1/3/2024: Vita Inclinata Technologies venture capital transaction
Next: 1/3/2024: Manina Medtech venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on funding rounds that are announced publicly. VC investment data records on this site are derived from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary